Introduction
Cerebral amyloid angiopathy (CAA) is characterised by β-amyloid deposition in small to medium arteries, arterioles and capillaries of the cortex and leptomeninges 1 . MRI features include lobar cerebral microbleeds (best observed using iron sensitive sequences), leukoaraiosis, convexity subarachnoid haemorrhage, cortical superficial siderosis, and silent acute ischemic lesions, leading to the development of clinical (Boston) criteria for in vivo diagnosis. 2 CAA can present with intracranial haemorrhage, transient neurological episode (amyloid spells), rapidly progressive cognitive and neurological decline reflecting CAA related neuroinflammation, as well as more insidious cognitive impairment 3 . There is considerable evidence that Alzheimer's disease (AD) and CAA are mechanistically linked: 95% of pathology proven AD have a degree of CAA pathology 4 , ApoE4 is a risk factor for both AD and CAA 5 and 23% of patients with sporadic AD have imaging features of CAA 5 . Given that CAA pathology frequently accompanies AD, it may be difficult to unravel the relative contribution of each pathology in demented individuals. Whilst acetylcholinesterase inhibitors (AchEI) are widely used in AD, there is little evidence for the efficacy in patients with cognitive impairment in CAA, or in mixed disease. Here we report three patients with dementia fulfilling criteria for CAA, two with probable and one with possible AD, in whom AchEI resulted in marked cognitive improvement.
Case 1
Paterson, Abdi 4 An 81 year-old male was referred with a 3-year history of cognitive decline manifest as slowly progressive problems with episodic memory and planning. He had had a left posterior intracerebral bleed, histologically proven to be due to CAA, at the age of 64. After his stroke he was left with static problems with visual perception function, reading, writing and arithmetic. He had a subsequent haemorrhagic stroke at the age of 80 causing dysarthria and dyspraxia but he and his wife were clear that cognitive problems had emerged prior to this event and continued to worsen since. Table) .
Case 2
A 68 year-old female with a history of ischemic heart disease presented with a 3-year history of impairments of episodic memory, navigational skills, and behavioural 
Discussion
In AD trials individuals typically improve by 1-2 MMSE points following AchEI treatment, 7 and so the marked cognitive (11, 9 and 6 MMSE points) and functional improvements in these three cases are striking. Most significant improvements were Paterson, Abdi 6 in attention and language. All individuals had several years of cognitive symptoms and significant cognitive impairment by the time treatment was commenced, One explanation for the marked treatment response might be their degree of impairment: despite having moderately severe dementia, the pathological evidence of CAA and prior strokes in the first case, and presence of significant white matter changes in the second and third, meant that AD had not previously been considered, and none had been trialled on an AchEI when less severely affected. Another possibility is that the combination of CAA and AD pathology is associated with a more pronounced cholinergic deficit, predicting a greater response to AchEI treatment. These cases demonstrate the difficulties in ascribing cognitive deficits to CAA or AD pathology, and suggest that AchEI treatment should be considered in patients with CAA and cognitive decline. 
Supplemental video
The individual described in case 1 and his wife describe an improvement in symptoms 3 months after starting AchEI donepezil (10mg). Highlights  CAA pathology frequently accompanies AD pathology  CAA and AD pathology are likely to be mechanistically linked  Individuals with AD pathology alone typically benefit from a modest cognitive improvement with AchEI (~2 MMSE points)  We observe a striking cognitive improvement in 3 individuals with co-existing CAA and AD when treated with AchEI
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